Abagovomab for ovarian cancer (Q37829443)

24 August 2017

1 reference

title

Abagovomab for ovarian cancer (English)

1 reference

24 August 2017

1 reference

Jacobus Pfisterer

1

1 reference

24 August 2017

Philipp Harter

2

1 reference

24 August 2017

Cecilia Simonelli

3

1 reference

24 August 2017

Martin Peters

4

1 reference

24 August 2017

Jonathan Berek

5

1 reference

24 August 2017

Paul Sabbatini

6

1 reference

24 August 2017

Andreas du Bois

7

1 reference

24 August 2017

language of work or name

English

0 references

publication date

18 January 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

3

1 reference

24 August 2017

395-403

1 reference

24 August 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Biologic and Immunologic Therapies for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.553598

10.1517/14712598.2011.553598

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference